UCB and Biogen say their first phase 3 trial of their systemic lupus erythematosus (SLE) candidate dapirolizumab pegol was a success, and a second is now expected to start before the end of the year.
GSK plans phase 3 for hepatitis B drug bepirovirsen, despite efficacy drop GSK has revealed updated results from its phase 2b trial of its antisense drug for hepatitis B virus (HBV) infections, which ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback